Letters
Guidance on collaboration with drug industry
Guidance offers little in the way of ethics or transparency
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2910 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2910- Wendy Rogers, professor of clinical ethics1,
- Tamara Zutlevics, visiting scholar 2,
- Melissa Raven, adjunct lecturer2,
- Jon Jureidini, head3
- 1Macquarie University, Sydney, NSW 2109, Australia
- 2Flinders University, Adelaide, SA, Australia
- 3Department of Psychological Medicine, Women’s and Children’s Hospital, Adelaide, SA, Australia
- wendy.rogers{at}mq.edu.au
While noting the alleged benefits of this new guidance, the article fails to mention its weaknesses.1 The guidance uncritically endorses relationships between the drug industry and healthcare professionals, a view endorsed by 18 august bodies including various royal colleges.
Despite claims of “ethics, transparency, partnership,” it takes some sleuthing to discover that the guideline is written by a multi-stakeholder group, seemingly coordinated and supported …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.